Open AccessDeciphering Antitumor Mechanism of Pien Tze Huang in Mice of Hepatocellular Carcinoma Based on Proteomics
Author(s) -
Dancai Fan,
Chang Liu,
Li Li,
Cheng Lü,
Ning Zhao,
Jun Shu,
Xiaojuan He,
Aiping Lu
Publication year - 2020
Publication title -
journal of immunology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.315
H-Index - 83
eISSN - 2314-8861
pISSN - 2314-7156
DOI - 10.1155/2020/4876251
Subject(s) - cancer research , cell cycle , hepatocellular carcinoma , cancer , cell cycle checkpoint , cell growth , downregulation and upregulation , signal transduction , medicine , pharmacology , chemistry , biochemistry , gene
The Chinese formula Pien Tze Huang (PZH) has been used to treat hepatocellular carcinoma (HCC) and showed positive clinical effects. However, the antitumor mechanism of PZH in HCC remains unclear. In this study, HCC xenograft Balb/c mice were treated with PZH; then, proteomics detection and Ingenuity Pathway Analysis (IPA) were used to analyze the differentiated phosphorylated proteins in tumor tissues. The results indicated that PZH could inhibit tumor weight by 50.76%. Eighty-four upregulated and 11 downregulated phosphorylated proteins were identified in PZH-treated mice. Twenty signaling pathways were associated with inflammation (including the IL-6 and TNFR1/2 pathways), cancer growth (including the p53 and FAK pathways), and the cell cycle (including the G2/M and G1/S checkpoint regulation pathways). Moreover, TNF- α , IL-6, and several typical differentially expressed phosphorylated proteins (such as p-CCNB1, p-FOXO3, and p-STAT3) in tumor tissues, tumor cell viability, and cell cycle arrest assay in vitro further verify the results of IPA. These results revealed that PZH achieved antitumor activity in HCC; the underlying mechanisms of which were mainly through regulating the inflammation-associated cytokine secretion, cancer growth pathways, and induction of G2/M arrest. These data provided the potential molecular basis for PZH to act as a therapeutic drug or a supplement to chemotherapy drugs for human HCC in the future.